Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Pharma
Merck's Keytruda helps early-stage TNBC patients live longer
Keytruda’s survival benefit in early-stage triple-negative breast cancer sets it apart from Roche’s Tecentriq, which has failed twice in the disease.
Angus Liu
Sep 15, 2024 8:10am
AstraZeneca stands by Truqap despite surprise breast cancer flop
Sep 13, 2024 10:00am
Merck, AstraZeneca, Gilead: The race for supremacy in an ADC field
Aug 2, 2024 4:00pm
AZ's Truqap came up short in triple-negative breast cancer study
Jun 18, 2024 9:09am
Roche's new pharma chief talks Tecentriq in early cancers
Apr 26, 2023 9:17am
VMLY&R, Gilead use AI to turn patient testimonies into paintings
Feb 16, 2023 10:15am
